Abstract
Since its first reported use in humans in 1981 [1], 131I-meta-iodobenzylguanidine (MIBG) has been used with success for the scintigraphic diagnosis of a variety of neuroendocrine tumours [2]. Derived from the neural crest, many of these tumours maintain the characteristic features of these cells, such as an active uptake-1 mechanism at the cell membrane and neurosecretory storage granules in the cytoplasm, which are responsible for the specific uptake and retention of MIBG.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sisson, J.C., Frager, M.S., Valk, T.W. et al. (1981) Scintigraphic localization of pheochromocytoma. N. Engl J. Med., 305, 12–17.
Hoefnagel, C.A. (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur. J. Nucl. Med., 21, 561–81.
Khafagi, F.A., Shapiro, B., Fig, L.M. et al. (1989) Labetalol reduces iodine-131 MIBG uptake by pheo-chromocytoma and normal tissues. J. Nucl. Med., 30, 481–9.
Hoefnagel, C.A., Voûte, P.A., de Kraker, J. et al. (1987) Radionuclide diagnosis and therapy of neural crest tumors using Iodine-131 metaiodobenzylguanidine. J. Nucl. Med., 28, 308–14.
Lashford, L.S., Lewis, I.J., Fielding, S.L. et al. (1992) Phase I/II study of Iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J. Clin. Oncol., 10, 1889–96.
Van der Steen, J., Maessen, H.J.M., Hoefnagel, C.A. et al. (1986) Radiation protection during treatment of children with 131I-meta-iodobenzylguanidine. Health Physics, 50, 515–22.
Wafelman, A.R., Suchi, R., Hoefnagel, C.A. et al. (1993) Radiochemical purity of 131I-MIBG infusion fluids: a report from the clinical practice. Eur. J. Nucl. Med., 20, 614–16.
Bravo, E.L., Gifford, R.W. and Manger, W.M. (1993) Adrenal medullary tumors: pheochromocytoma, in Endocrine Tumors (eds L. Mazzaferri and N.A. Samaan), Blackwell, Oxford, pp. 426–47.
Sisson, J.C., Shapiro, B., Beierwaltes, W.H. et al. (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med., 24, 197–206.
Troncone, L. and Galli, G. (1991) Proceedings International Workshop on the role of [131I]-metaiodobenzylguanidine in the treatment of neural crest tumors. J. Nucl. Biol. Med., 35, 177–362.
Baulieu, J.-L., Guilloteau, D., Baulieu, F. et al. (1988) Therapeutic effectiveness of Iodine-131 MIBG metastases of a nonsecreting paraganglioma. J. Nucl. Med., 29, 2008–13.
Voûte, P.A., de Kraker, J. and Hoefnagel, C.A. (1992) Tumours of the sympathetic nervous system. Neuroblastoma, ganglioneuroma and phaeochromocytoma, in Cancer in children: Clinical management (eds P.A. Voûte, A. Barrett and J. Lemerle), Springer, Berlin, pp. 226–43.
Rutgers, M., Tytgat, G.A.M., Verwijs-Janssen, M. et al. (1993) Uptake of the neuron-blocking agent metaiodobenzylguanidine and serotonin by human platelets and neuroadrenergic tumour cells. Int. J. Cancer, 54, 290–5.
Sisson, J.C., Hutchinson, R.J., Carey, J.E. et al. (1988) Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine. Eur. J. Nucl. Med., 14, 337–40.
Hoefnagel, C.A., de Kraker, J., Valdés Olmos, R.A. et al. (1994) 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl. Med. Commun., 15, 712–17.
Samaan, N.A., Ordónez, N.G. and Hickey, R.C. (1993) Medullary thyroid carcinoma, in Endocrine Tumors (eds L. Mazzaferri and N.A. Samaan), Blackwell, Oxford, pp. 334–47.
Feldman, J.M. (1993) Carcinoid tumors, in Endocrine Tumors (eds L. Mazzaferri and N.A. Samaan), Blackwell, Oxford, pp. 700–22.
Taal, B.G., Hoefnagel, C.A., Valdés Olmos, R.A. et al. The palliative effect of metaiodobenzylguanidine (MIBG) in metastatic carcinoid tumors. J. Clin. Oncol., 14, 1829–38.
Sisson, J.C., Hutchinson, R.J., Shapiro, B. et al. (1990) Iodine-125-MIBG to treat neuroblastoma: preliminary report. J. Nucl. Med., 31, 1479–85.
Hoefnagel, C.A., Smets, L., Voûte, P.A. et al. (1991) Iodine-125-MIBG therapy for neuroblastoma. J. Nucl. Med., 31, 361–2.
Mairs, R.J., Russell, J., Cunningham, S. et al. (1995) Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I] metaiodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur. J. Cancer, 31 A, 576–81.
Rutgers, M., Buitenhuis, C.K.M. and Smets, L.A. Pre-dosing with MIBG to improve the relative neuroblastoma over normal tissue exposure of 131I-MIBG in animal models. Horm. Metab. Res. (in press).
Blake, G.M., Lewington, V.J., Fleming, J.S. et al. (1988) Modification by nifedipine of I metaiodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur. J. Nucl. Med., 14, 345–8.
Voûte, P.A., van der Kleij, A.J., de Kraker, J. et al. (1995) Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur. J. Cancer, 31A, 596–600.
Further Reading
Hoefnagel, C.A. (1989) The Clinical Use of 131 I-metaiodobenzylguanidine (MIBG) for the diagnosis and treatment of neural crest tumors. Thesis, University of Amsterdam, ISBN 90–9003051–4.
Mazzaferri, L. and Samaan, N.A. (eds) (1993) Endocrine Tumors, Blackwell, Oxford.
Moertel, C.G. (1987) Karnofsky memorial lecture. An Odyssey in the land of small tumors. J. Clin. Oncol., 5, 1502–22.
Troncone, L., Rufini, V., Montemaggi, P. et al. (1990) The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur. J. Nucl. Med., 16, 325–35.
Voûte, P.A., de Kraker, J. and Hoefnagel, C.A. (1992) Tumours of the sympathetic nervous system. Neuroblastoma, ganglioneuroma and phaeocnromocytoma, in Cancer in children: Clinical management (eds P.A. Voûte, A. Barrett and J. Lemerle), Springer, Berlin, pp. 226–43.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Hoefnagel, C.A. (1998). Neuro-ectodermal tumours. In: Maisey, M.N., Britton, K.E., Collier, B.D. (eds) Clinical Nuclear Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-3356-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-4899-3356-0_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-412-75180-6
Online ISBN: 978-1-4899-3356-0
eBook Packages: Springer Book Archive